Trump sends letters to pharmaceutical CEOs demanding drug price relief

president Donald Trump says Americans pay a lot against prescribed medications, and demands change.

He sent 17 letter to the drug managers on Thursday, saying that he would only accept an obligation to provide an immediate mitigation of “largely enlarged drug prices.”

The president wants other rich countries to help bearing the cost of research and developing branded drugs that can help reduce the price of these drugs.

“The days of foreign countries have ended from starting from the United States of America the moment President Trump takes office,” said Kush Desi, a spokesman for Fox Business.

“The Americans are only 5 % of the world’s population, but they finance 75 % of the profits of pharmaceutical companies, all because Americans are bore several times on the same micro -drugs enjoyed by people in other wealthy countries.

“President Trump has pledged to reduce drug prices for ordinary Americans, and the administration takes historical measures to ensure that the pharmaceutical companies will make the wealthy countries pay their fair share instead of continuing to tear the American people.”

HHS SEC Robert F Kennedy Jr: American patients pay more so that others can pay less – stop now

Astrazeneca building (Istock)

Pascal Soreriot, CEO of Astrazeneca, said exclusively to Fox Business in an interview with him recently.

“For many years, the United States was covering the cost of research and development in our industry. It is very important, of course, this drug saves lives,” Soreut said. “American patients benefit first in front of anyone else in the world. This industry creates a lot of good functions. Therefore, America gets benefits from this.

“However, at some point, this cost of research and development must be shared somewhat across the rich countries. I am talking about rich countries, as in Europe or Japan, which has enough GDP to finance these. So, I completely support the idea that there is some price equation that may be modified by the gross domestic product between countries.”

Pharma Giant, which treats its higher drugs for diabetes and cancer among other diseases, has announced an investment of $ 50 billion over the next five years in the United States.

Astrazeneca to invest 50 billion dollars in us

CVS pharmacy counter (Jeffrey Greenberg/Eduction Images/Universal Images Group via Getty Images/Getty Images)

The Trump administration plans to use power under the office of the American Trade Representative and the Ministry of Commerce to monitor the progress of the drug re -balance. White House officials hope that this is a cooperative effort with pharmaceutical companies and likened to expanding his hand to help other countries exchange the cost burden for medicines.

These officials prefer to change the cost structure of the prescribed medicines through a voluntary process, but they say that the administration is happy to force them through a mandatory organizational process.

Pfizer, Eli Lilly, Merck, Gilead and AMGEN are among the companies that have received messages where the president puts four areas where pharmaceutical companies can make changes that reduce prices:

1. To extend the prices of the most preferred nation to Medicaid
2. Ensure the prices of the most preferred nation for the newly launched drugs
3. The return of increased revenues from abroad from balance to American patients
4. Providing direct distributions to the consumer or direct to the business to get rid of the middle man in order to save costs

Get Fox Business on the Go by clicking here

He said that the president has set a final date on September 29 for re -restriction or that his team is ready to help.

Fox Business’ Suzanne O’Hallran has contributed to this report.